head-icon1.svgMeet us at an upcoming event
head-icon2.svgIn Stock. Ready to Ship
languageEN
languageEN
icon-arrow-g
counsellingContact Us
languageEN
languageEN
icon-arrow-g

background-image

Metabolism

Tirzepatide and Efruxifermin Demonstrate Therapeutic Benefits for NASH in a Preclinical Metabolic Syndrome Animal Model, B6-Alms1-del Mice

2024-07-27

1744098712390027993_undefined.jpeg

Download download

To assess treatments for MASLD and its severe form, MASH, GemPharmatech developed the B6-Alms1-del mouse model. Previous studies have shown that this model spontaneously develops metabolic syndrome (including obesity, hyperglycemia, hyperinsulinemia, and dyslipidemia) and MASH, with these conditions mitigated by treatment with the GLP-1R agonist semaglutide. In this study, we evaluated two additional promising anti-MASH agents, Tirzepatide (a GLP-1R & GIPR dual agonist) and Efruxifermin (an FGF21 analog, also known as AKR001), using the B6-Alms1-del MASH animal model.


Prevarrow-right-warrow-right-g

Recommended for You

More infomation about blogs

background-image

Find Models

Contact Our Teamarrow-right-garrow-right-w
Request Quotearrow-right-garrow-right-w

Submit Inquiry

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

Additional Info

Submitarrowarrow

Contact Us

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

How did you hear about us*

Select a source

Leave us a message

Submitarrowarrow

Schedule a Meeting

Let us know which event you're attending and we'd be happy to connect with you.

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

How did you hear about us*

Select a source

Leave us a message

Submitarrowarrow

Download

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Download

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Watch On-Demand Webinar

First Name*

Last Name*

Organization*

Email*

Country/Region

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Newsletter Signup

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

Area of interest*

Select Area of Interest

Research Focus

Submitarrowarrow